CoJourney

CoJourney

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CoJourney is a specialized CDMO focused on accelerating the development and manufacturing of advanced cell and gene therapies. Founded in 2019 and headquartered in Boston with significant operations in Horsham, PA and Hangzhou, China, the company leverages its proprietary Zero Chrom® plasmid platform and viral vector expertise to offer high-yield, cost-effective manufacturing solutions. With over 100 clients served and a recent $30 million financing round, CoJourney is positioned as a key enabler for biotechs navigating complex CMC and regulatory pathways.

Digital HealthAI / Machine Learning

Technology Platform

Proprietary Zero Chrom® plasmid manufacturing platform for high-purity, low-cost production; scalable viral vector (AAV, Lenti), sgRNA, and exosome manufacturing platforms.

Opportunities

The global cell and gene therapy CDMO market is experiencing massive growth due to a booming clinical pipeline and chronic manufacturing capacity shortages.
CoJourney's cost-reducing Zero Chrom platform directly addresses the major affordability challenge in the sector, positioning it as a key enabler for more commercially viable therapies.

Risk Factors

Key risks include dependency on the success and funding of its biotech clients, intense competition from larger established CDMOs, and the operational and reputational risks associated with complex GMP manufacturing where any batch failure or quality lapse can be catastrophic.

Competitive Landscape

CoJourney competes in the fragmented but growing advanced therapies CDMO space against giants like Lonza, Catalent, and Thermo Fisher, as well as specialized peers like Oxford Biomedica, Genezen, and Vigene Biosciences. Its differentiation hinges on its proprietary, cost-focused plasmid platform and integrated service offering for key gene therapy raw materials.